Insider · CIK 0001638380

Ward Shane

Reports to the SEC for 3 companies · SAN DIEGO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001638380

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-01-07	CDTXCidara Therapeutics, Inc.D Disposition to Issuer	COO & CLO	DDisposition to Issuer	−25.1K sh	$221.50	−$5.56M	0
2026-01-07	CDTXCidara Therapeutics, Inc. · Employee Stock Option (right to buy)D Disposition to Issuer	COO & CLO	DDisposition to Issuer	−12.5K sh	—	—	0
2026-01-07	CDTXCidara Therapeutics, Inc. · Employee Stock Option (right to buy)D Disposition to Issuer	COO & CLO	DDisposition to Issuer	−6,207 sh	—	—	0
2026-01-07	CDTXCidara Therapeutics, Inc. · Employee Stock Option (right to buy)D Disposition to Issuer	COO & CLO	DDisposition to Issuer	−12.5K sh	—	—	0
2026-01-07	CDTXCidara Therapeutics, Inc. · Employee Stock Option (right to buy)D Disposition to Issuer	COO & CLO	DDisposition to Issuer	−136K sh	—	—	0
2026-01-07	CDTXCidara Therapeutics, Inc. · Employee Stock Option (right to buy)D Disposition to Issuer	COO & CLO	DDisposition to Issuer	−50K sh	—	—	0
2025-12-10	CDTXCidara Therapeutics, Inc.F Tax Payment	COO & CLO	FTax Payment	−15K sh	$219.60	−$3.3M	24,633
2025-12-10	CDTXCidara Therapeutics, Inc.M Exercise/Conversion	COO & CLO	MExercise/Conversion	+3,500 sh	$16.65	+$58.3K	28,133
2025-12-10	CDTXCidara Therapeutics, Inc.M Exercise/Conversion	COO & CLO	MExercise/Conversion	+6,459 sh	$20.20	+$130K	34,592
2025-12-10	CDTXCidara Therapeutics, Inc.S Sale	COO & CLO	SSale	−9,959 sh	$220.08	−$2.19M	25,033
2025-12-10	CDTXCidara Therapeutics, Inc. · Employee Stock Option (right to buy)M Exercise/Conversion	COO & CLO	MExercise/Conversion	−3,500 sh	—	—	0
2025-12-10	CDTXCidara Therapeutics, Inc. · Employee Stock Option (right to buy)M Exercise/Conversion	COO & CLO	MExercise/Conversion	−6,459 sh	—	—	6,207
2025-03-31	CDTXCidara Therapeutics, Inc.A Award	COO & CLO	AAward	+25K sh	—	—	39,674
2025-03-31	CDTXCidara Therapeutics, Inc. · Employee Stock Option (right to buy)A Award	COO & CLO	AAward	+50K sh	—	—	50,000
2025-03-11	CDTXCidara Therapeutics, Inc.S Sale	COO & CLO	SSale	−1,664 sh	$21.96	−$36.5K	14,674
2024-09-30	CDTXCidara Therapeutics, Inc. · Employee Stock Option (right to buy)A Award	COO & CLO	AAward	+136K sh	—	—	135,540
2024-03-15	CDTXCidara Therapeutics, Inc.A Award	COO & CLO	AAward	+120K sh	—	—	318,770
2024-03-15	CDTXCidara Therapeutics, Inc. · Employee Stock Option (right to buy)A Award	COO & CLO	AAward	+250K sh	—	—	250,000
2024-03-11	CDTXCidara Therapeutics, Inc.S Sale	COO & CLO	SSale	−20.5K sh	$0.67	−$13.7K	198,770
2023-03-27	CDTXCidara Therapeutics, Inc.A Award	COO & CLO	AAward	+127K sh	—	—	211,243
2023-03-27	CDTXCidara Therapeutics, Inc. · Employee Stock Option (right to buy)A Award	COO & CLO	AAward	+253K sh	—	—	253,333
2023-03-13	CDTXCidara Therapeutics, Inc.S Sale	COO & CLO	SSale	−4,329 sh	$1.53	−$6,623.37	84,576
2022-03-31	CDTXCidara Therapeutics, Inc.A Award	COO & CLO	AAward	+35K sh	—	—	35,000
2022-03-31	CDTXCidara Therapeutics, Inc.A Award	COO & CLO	AAward	+69K sh	—	—	104,027
2022-03-31	CDTXCidara Therapeutics, Inc.F Tax Payment	COO & CLO	FTax Payment	−23.1K sh	$0.83	−$19.2K	80,905
2022-03-31	CDTXCidara Therapeutics, Inc. · Employee Stock Option (right to buy)A Award	COO & CLO	AAward	+70K sh	—	—	70,000
2021-08-25	CDTXCidara Therapeutics, Inc. · Stock Option (right to buy)A Award	COO & CLO	AAward	+250K sh	—	—	250,000
2020-05-29	BELLICUM PHARMACEUTICALS, INCF Tax Payment	Sr VP and Chief Legal SO	FTax Payment	−107 sh	$7.63	−$816.41	1,879
2020-04-08	BELLICUM PHARMACEUTICALS, INCRestricted Stock UnitsA Award	Sr VP and Chief Legal SO	AAward	+21.9K sh	—	—	21,864
2020-02-03	BELLICUM PHARMACEUTICALS, INCStock Option (right to buy)A Award	Sr VP and Chief Legal SO	AAward	+410K sh	—	—	410,000
2019-08-29	BELLICUM PHARMACEUTICALS, INCP Purchase	Sr VP and Chief Legal SO	PPurchase	+8,000 sh	$1.23	+$9,821.6	18,294
2019-06-11	BELLICUM PHARMACEUTICALS, INCStock Option (right to buy)A Award	Sr VP and Chief Legal SO	AAward	+45K sh	—	—	45,000
2019-05-29	BELLICUM PHARMACEUTICALS, INCF Tax Payment	Sr VP and Chief Legal SO	FTax Payment	−1,065 sh	$2.09	−$2,225.85	8,935
2019-02-01	BELLICUM PHARMACEUTICALS, INCStock Option (right to buy)A Award	Sr VP and Chief Legal SO	AAward	+45K sh	—	—	45,000
2018-05-29	BELLICUM PHARMACEUTICALS, INCA Award	Sr VP and Chief Legal SO	AAward	+10K sh	—	—	10,000
2018-05-29	BELLICUM PHARMACEUTICALS, INCEmployee Stock Option (right to buy)A Award	Sr VP and Chief Legal SO	AAward	+120K sh	—	—	120,000
2018-02-08	Aravive, Inc.S Sale	SVP and General Counsel	SSale	−4,118 sh	$1.80	−$7,412.4	201,556
2017-12-20	Aravive, Inc.A Award	SVP and General Counsel	AAward	+93.1K sh	—	—	205,674
2017-11-28	Aravive, Inc.A Award	SVP and General Counsel	AAward	+20K sh	—	—	112,574
2017-10-19	Aravive, Inc.S Sale	SVP and General Counsel	SSale	−776 sh	$2.55	−$1,978.8	92,574
2017-10-06	Aravive, Inc.A Award	SVP and General Counsel	AAward	+57K sh	—	—	93,350
2017-03-15	Aravive, Inc.S Sale	SVP and General Counsel	SSale	−776 sh	$19.02	−$14.8K	36,350
2017-03-14	Aravive, Inc.S Sale	SVP and General Counsel	SSale	−1,265 sh	$19.00	−$24K	37,126
2017-01-30	Aravive, Inc.S Sale	SVP and General Counsel	SSale	−1,474 sh	$13.85	−$20.4K	38,391
2017-01-27	Aravive, Inc.A Award	SVP and General Counsel	AAward	+20.6K sh	—	—	39,865
2017-01-27	Aravive, Inc.Stock Option (Right to Buy)A Award	SVP and General Counsel	AAward	+46.2K sh	—	—	46,200
2016-10-11	Aravive, Inc.A Award	SVP and General Counsel	AAward	+5,000 sh	—	—	19,265
2016-01-28	Aravive, Inc.A Award	SVP and General Counsel	AAward	+13K sh	—	—	14,265
2016-01-28	Aravive, Inc.Stock Option (Right to Buy)A Award	SVP and General Counsel	AAward	+42K sh	—	—	42,000
2015-04-06	Aravive, Inc.Stock Option (Right to Buy)A Award	SVP and General Counsel	AAward	+50K sh	—	—	50,000

Recent filings

Accepted (ET)
Jan 74
Ward Shane0001638380-26-000002
SEC(opens sec.gov)
Dec 124
Ward Shane0001610618-25-000100
SEC(opens sec.gov)
Apr 24
Ward Shane0001610618-25-000027
SEC(opens sec.gov)
Mar 134
Ward Shane0001610618-25-000024
SEC(opens sec.gov)
Oct 24
Ward Shane0001610618-24-000129
SEC(opens sec.gov)
Mar 204
Ward Shane0001610618-24-000027
SEC(opens sec.gov)
Mar 124
Ward Shane0001610618-24-000012
SEC(opens sec.gov)
Mar 294
Ward Shane0001610618-23-000036
SEC(opens sec.gov)

Companies

Address

6310 NANCY RIDGE DRIVE SUITE 101

SAN DIEGO, CA, 92121